UNIVERSITAS
GADJAH MADA
Evaluasi Faktor yang Berhubungan dengan Efektivitas Terapi Imatinib pada Pasien Chronic Myeloid Leukemia (CML)
Niky Budiarti, Prof. Dr. apt. Zullies Ikawati; Prof. Dr. apt. Arief Nurrochmad, M.Si, M.Sc
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Abood, R. A., Hasson, H. M., Khalaf, A. A., and Saleh, E. M. 2019, Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index, *Sultan Qaboos Univ. Med. J.*, **19**:236–241.

Adattini, J. A., Gross, A. S., Wong Doo, N., and McLachlan, A. J. 2022, Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience, *Pharmacol. Res. Perspect.*, **10**:1–21.

Adawi, D. H., Al-barghouthi, A., Fredj, N. B., Lubada, M., Njjar, D. O., Ruzaygat, M., *et al*. 2025, Genetic and Non-genetic Correlates of Imatinib Pharmacokinetics and Side Effects of Imatinib in Palestinian Patients with Chronic Myeloid Leukemia, *Biochem. Genet.*

Ali, M. A. M. 2016, Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy, *Mol. Diagn. Ther.*, **20**:315–333.

Anonim. 2017, *Common Terminology Criteria for Adverse Events (CTCAE) v 5.0*, U.S. Department of Health and Human Services.

Athale, U., Hijiya, N., Patterson, B. C., Bergsagel, J., Jeffrey, R., Bittencourt, H., *et al*. 2020, Management of Chronic Myeloid Leukemia (CML) in Children and Adolescents: Recommendations from the Children's Oncology Group CML Working Group Uma, *Pediatr. Blood Cancer*, **66**:1–23.

Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., *et al*. 2009, Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet, *J. Clin. Oncol.,* **27**:6041–6051.

Bandyopadhyay, A., Palepu, S., Dhamija, P., Nath, U. K., Chetia, R., Bakliwal, A., *et al*. 2023, Safety and efficacy of Vitamin D(3) supplementation with Imatinib in Chronic Phase- Chronic Myeloid Leukaemia: an Exploratory Randomized Controlled Trial, *BMJ Open*, **13**:e066361.

Branford, S., Yeung, D. T., Ross, D. M., Prime, J. A., Field, C. R., Altamura, H. K., *et al*. 2013, Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML, *Blood*, **121**: 3818–3824.

UNIVERSITAS
GADJAH MADA
Evaluasi Faktor yang Berhubungan dengan Efektivitas Terapi Imatinib pada Pasien Chronic Myeloid Leukemia (CML)
Niky Budiarti, Prof. Dr. apt. Zullies Ikawati; Prof. Dr. apt. Arief Nurrochmad, M.Si, M.Sc
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., *et al*. 2015, Differences among young adults, adults and elderly chronic myeloid leukemia patients. *Ann. Oncol.*, **26**:185–192.

Cha, S. H., Kim, K., and Song, Y. K. 2023, Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis, *Acta Oncol.,* **62**: 1767–1774.

Charlson, M. E., Carrozzino, D., Guidi, J., and Patierno, C. 2022, Charlson Comorbidity Index : A Critical Review of Clinimetric Properties, *Psychother. Psychosom*., **91**:8–35.

Cheng, F., Cui, Z., Li, Q., Wang, L., and Li, W. 2023a, Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia, *Int. Immunopharmacol.,* **124**:1-6.

Cheng, F., Yuan, G., Li, Q., Cui, Z., and Li, W. 2023b, Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China, *Front. Oncol*., **13**:1172910.

Cheng, F., Zeng, F., Li, Q., Cui, Z., Chen, Y., Li, W., *et al*. 2022, Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia, *Cancer*, **128**: 3951–3958.

Chetia, R., Palepu, S., Dutta, V., Bandyopadhyay, A., Mathew, A., Vaniyath, S., *et al*. 2024, Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial, *South Asian J. Cancer*, **14**:608–614.

Clarke, W. A., Chatelut, E., Fotoohi, A. K., Larson, R. A., Martin, J. H., Mathijssen, R. H. J., *et al*. 2021, Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy, *Eur. J. Cancer*, **157**:428–440.

Cortes, J., Pavlovsky, C., and Saußele, S. 2021, Chronic myeloid leukaemia, *Lancet*, **398**:1914–1926.

Costa, A., Scalzulli, E., Carmosino, I., Bisegna, M. L., Laganà, A., Ielo, C., *et al*. 2026, Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study, *Br J Haematol*, **00**:1–10.

Derakhshan, A., Mansouri, A., Kohneloo, A. J., and Hadjibabaie, M. 2023, Adherence to Immunosuppressants among Adult Patients after Allogeneic

UNIVERSITAS
GADJAH MADA
Evaluasi Faktor yang Berhubungan dengan Efektivitas Terapi Imatinib pada Pasien Chronic Myeloid Leukemia (CML)
Niky Budiarti, Prof. Dr. apt. Zullies Ikawati; Prof. Dr. apt. Arief Nurrochmad, M.Si, M.Sc
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Hematopoietic Stem-Cell Transplantation (Allo-HSCT): A Cross-Sectional Study, *Int. J. Hematol. Oncol. Stem Cell Res.*, **17**:231–239.

Di Felice, E., Roncaglia, F., Venturelli, F., Mangone, L., Luminari, S., Cirilli, C., *et al*. 2018, The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: A population-based study, *BMC Cancer*, **18:**1–12.

Farmer, K. C. 1999, Methods for Measuring and Monitoring Medication Regimen Adherence in Clinical Trials and Clinical Practice, *Clin. Ther.*, **21**:1074–1090.

Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., *et al*. 2024, Global Cancer Observatory: Cancer Today, Lyon, France, International Agency for Research on Cancer, available from https://gco.iarc.who.int/today, accessed 2024.

García-queiruga, M., Martínez-lópez, L. M., Martín-herranz, M. I., Seoane-pillado, T., Fernández-gabriel, E., and Calleja-chuclá, T. 2016, Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic response. *Farm Hosp.*, **40**:141–149.

Guilhot, F., and Hehlmann, R. 2025, Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia. *Blood*, **145**: 910–920.

Guilhot, F., Rigal-Huguet, F., Guilhot, J., Guerci-Bresler, A. P., Maloisel, F., Rea, D., *et al*. 2021, Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial, *Leukemia*, **35**:2332–2345.

Ibrahim, A. R., Eliasson, L., Apperley, J. F., Milojkovic, D., Bua, M., Szydlo, R., *et al*. 2011, Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy, *Blood*, **117**:3733–3736.

Jabbour, E., and Kantarjian, H. 2020, Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring, *Am. J. Hematol.*, **95**:691–709.

Jabbour, E., and Kantarjian, H. 2022, Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring, *Am. J. Hematol.*, **97**:1236–1256.

Jabbour, E., and Kantarjian, H. 2025, Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. *Am. J. Hematol.*, **99**:2191–2212.

UNIVERSITAS
GADJAH MADA
Evaluasi Faktor yang Berhubungan dengan Efektivitas Terapi Imatinib pada Pasien Chronic Myeloid Leukemia (CML)
Niky Budiarti, Prof. Dr. apt. Zullies Ikawati; Prof. Dr. apt. Arief Nurrochmad, M.Si, M.Sc
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P., *et al*. 2021, Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis., *Leukemia*, **35**:440–453.

Kementerian Kesehatan Republik Indonesia. 2023, Peraturan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/2197/2023 tentang Formularium Nasional, Jakarta.

Khan, A., Rasheed, F., Bader, Z., and Aamir, I. 2025, Age, Gender and Genetic Code: Exploring imatinib Mesylate therapeutic response with the role of rs683369 in chronic myeloid leukemia, *Prof. Med. J.*, **32**:1280–1287.

Kim, D. D. H., Novitzky-Basso, I., Kim, T. S., Atenafu, E. G., Forrest, D., Savoie, L., *et al*. 2021a, Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial, *Br. J. Haematol.*, **193**:779–791.

Kim, Y., Go, T.-H., Jang, J., Lee, J. B., Lim, S. T., Shim, K. Y., et al. 2021b, Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia, *Korean J. Intern. Med.*, **36**:1450–1458.

Kronick, O., Chen, X., Mehra, N., Varmeziar, A., Fisher, R., Kartchner, D., *et al*. 2023, Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis, *Cancers (Basel)*, **15**:4354.

Lee, H., Basso, I. N., and Kim, D. D. H. 2021, Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia, *Int. J. Hematol.*, **113**:632–641.

Li, Z., Zhang, X., Zhao, Y., Lu, L., Guo, Y., Gale, R. P., *et al*. 2024, Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia, *Cancer*, **131**:e35565

Lin, Q., Mao, L., Shao, L., Zhu, L., Han, Q., Zhu, H., *et al*. 2020, Global, Regional, and National Burden of Chronic Myeloid Leukemia, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017, *Front. Oncol.*, **10**:580759.

Lipton, J. H., Brümmendorf, T. H., Gambacorti-Passerini, C., Garcia-Gutiérrez, V., Deininger, M. W., and Cortes, J. E. 2022, Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option, *Blood Rev.*, **56**:100968.

UNIVERSITAS
GADJAH MADA
Evaluasi Faktor yang Berhubungan dengan Efektivitas Terapi Imatinib pada Pasien Chronic Myeloid Leukemia (CML)
Niky Budiarti, Prof. Dr. apt. Zullies Ikawati; Prof. Dr. apt. Arief Nurrochmad, M.Si, M.Sc
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Marin, D., Bazeos, A., Mahon, F. X., Eliasson, L., Milojkovic, D., Bua, M., *et al*. 2010, Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib, *J. Clin. Oncol.*, **28**:2381–2388.

McRae-Clark, A. L., Baker, N. L., Sonne, S. C., DeVane, C. L., Wagner, A., and Norton, J. 2015, Concordance of Direct and Indirect Measures of Medication Adherence in A Treatment Trial for Cannabis Dependence, *J. Subst. Abuse Treat.*, **57**:70–74.

Mendizabal, A. M., Younes, N., and Levine, P. H. 2016, Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia, *Int. J. Hematol.*, **103**:70–78.

Merin, D., Krishna, A., Jayakumar, S., Mahima, A., Anila, K. N., and Sidharthan, N. 2023, Assessment of Imatinib as a Primary Treatment of Chronic Myeloid Leukemia in Chronic Phase: a Cohort Study, *J. Oncol. Pharm. Pract.*, **29**:547–556.

Michiels, S., Tricas-Sauras, S., Salaroli, A., Bron, D., Lewalle, P., Vanschoenbeek, K., *et al*. 2024, Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data, *Patient Prefer. Adherence*, **18**:1991–2006.

Minasian, L. M., O'Mara, A., and Mitchell, S. A. 2022, Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE® to Provide Two Distinct and Complementary Perspectives, *Patient Relat. Outcome Meas.*, **13**:249–258.

Mjali, A., & Abbas, S. K. 2021, Imatinib Mesylate Adherence in Chronic Myeloid Leukemia Patients: Data from Middle Euphrates Region of Iraq, *Syst. Rev. Pharm.*, **12**:83–87.

Mohanavelu, P., Mutnick, M., Mehra, N., White, B., Kudrimoti, S., Kluesner, K. H., *et al*. 2021, Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia, *Cancers (Basel)*, **13**:1643.

Nasser, A., Hussein, A., Chamba, C., Yonazi, M., Mushi, R., Schuh, A., *et al*. 2021, Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania, *Blood Adv.*, **5**:1403–1411.

O'Hara, D. V., Janse, R. J., Fu, E. L., Jardine, M. J., and Carrero, J. J. 2024, Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care, *Diabetes Res. Clin. Pract.*, **213**:111745.

UNIVERSITAS
GADJAH MADA
Evaluasi Faktor yang Berhubungan dengan Efektivitas Terapi Imatinib pada Pasien Chronic Myeloid Leukemia (CML)
Niky Budiarti, Prof. Dr. apt. Zullies Ikawati; Prof. Dr. apt. Arief Nurrochmad, M.Si, M.Sc
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Obeng-Kusi, M., MacDonald, K., van Lierde, M. A., Lee, C. S., De Geest, S., and Abraham, I. 2021, No margin for non-adherence: Probabilistic Kaplan-Meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study), *Leuk. Res.*, **111**:106734.

Ono, T., Takahashi, N., Kizaki, M., Kawaguchi, T., Suzuki, R., Yamamoto, K., Ohnishi, K., Naoe, T., and Matsumura, I. 2020, Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor. *Cancer Sci.*, **111**:3714–3725.

Peter, M. E., Zuckerman, A. D., Cooper, K., DeClercq, J., Choi, L., James, C., *et al*. 2021, Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy, *J. Manag. Care Spec. Pharm.*, **27**:882–890.

Phukan, A., Mandal, P. K., and Dolai, T. K. 2021, Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India, *Ann. Hematol.*, **100**:85–96.

Pophali, P. A., & Patnaik, M. M. 2016, The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia, *Cancer J.*, **22**:40–50.

Rajabto, W., Reksodiputro, A. H., Rinaldi, I., Tadjoedin, H., Priantono, D., and Angkasa, Y. K. 2022, Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia, *Siriraj Med. J.*, **74**:530–536.

Rasu, R. S., Hunt, S. L., Dai, J., Cui, H., Phadnis, M. A., and Jain, N. 2021, Accurate Medication Adherence Measurement Using Administrative Data for Frequently Hospitalized Patients, *Hosp. Pharm.*, **56**:451–461.

Rasu, R. S., Phadnis, M. A., Xavier, C., Dai, J., Hunt, S. L., and Jain, N. 2024, P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis, *Kidney Int. Rep.*, ***9***:2125–2133.

Reategui-Almonacid, Y., Miranda, M., Wilson, J., Tjioe, K. C., Johnston, L., Taylor, A. O., *et al*. 2025, Real-world data vs pivotal trial outcomes of imatinib in newly diagnosed chronic myeloid leukemia patients, *J Clin Oncol*, **43**: e18565.

Reksodiputro, A. H., Tadjoedin, H., Supandiman, I., Acang, N. A., Kar, A. S., Bakta, I. M., *et al*. 2015, Epidemiology Study and Mutation Profile of Patients with Chronic Myeloid Leukemia (CML) in Indonesia, *J. Blood Disord. Transfus.*, **06**:1–13.

UNIVERSITAS
GADJAH MADA
Evaluasi Faktor yang Berhubungan dengan Efektivitas Terapi Imatinib pada Pasien Chronic Myeloid Leukemia (CML)
Niky Budiarti, Prof. Dr. apt. Zullies Ikawati; Prof. Dr. apt. Arief Nurrochmad, M.Si, M.Sc
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Schnorrerova, P., Matalova, P., and Wawruch, M. 2024, Medication adherence: measurement methods and approaches, *Bratisl. Med. J.*, **125**: 264-273.

Shah, N. P., Bhatia, R., Altman, J. K., Amaya, M., Begna, K. H., Berman, E., *et al*. 2024, Chronic Myeloid Leukemia, Version 2, NCCN Clinical Practice Guidelines in Oncology, *J. Natl. Compr. Canc. Netw.*, **22**: 43–69.

Shirinova, A., Asadov, C., Hasanova, A., and Alimirzoyeva, Z. 2025, Unique Gender-Related Characteristics and Differences of Chronic Myeloid Leukemia Patients in Azerbaijan : A Retrospective Cohort Study, **17**: e94677.

Sumantri, A. F., Oehadian, A., Wijaya, I., Vidyaniati, P., and Rahmaniati, R. 2019, Therapeutic Responses of Imatinib and Nilotinib among CML Patients in Hasan Sadikin Hospital Bandung. *Indones. J. Cancer*, **12**:88.

Swain, T. R., Goutam, S., Jena, R. K., and Rout, N. 2022, Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience, *Indian J. Pharmacol.*, **54**:349–352.

Thaarup, M., Jacobsen, S., Nielsen, P. B., Nicolajsen, C. W., Eldrup, N., Petersen, C. N., *et al*. 2024, Adherence and Persistence to Antiplatelet Therapy in Lower Extremity Peripheral Arterial Disease: A Danish Population Based Cohort Study. *Eur. J. Vasc. Endovasc. Surg.*, **67**:948–957.

Urgessa, F., Lengiso, B., Tsegaye, A., Gebremedhin, A., Abdella, F., Tadesse, F., *et al*. 2024, Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study, *BMC Cancer*, **24**:530.

Yalçın, C., Orhan, B., Candar, Ö., Çubukçu, S., and Koca, T. G. 2025, A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia, *Ther Adv Hematol*, **16***:* 1–15.

Yassin, M. A., Abdulla, M. A., Chandra, P., Aldapt, M. B., Hamad, Y., Akiki, S. J., *et al*. 2019, Chronic Myeloid Leukemia in Adolescents and Young Adults: A Single Institute Experience, *Blood*, **134**:5915.